Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis

INTRODUCTION: Antifibrinolytic agents are commonly used during cardiac surgery to minimize bleeding. Because of safety concerns, aprotinin was withdrawn from the market in 2007. Since then, tranexamic acid (TXA) has become the antifibrinolytic treatment of choice in many heart centers. The safety pr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sander, Michael, Spies, Claudia D, Martiny, Viktoria, Rosenthal, Christoph, Wernecke, Klaus-Dieter, von Heymann, Christian
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2010
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2945131/
https://ncbi.nlm.nih.gov/pubmed/20682059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/cc9216
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars